Chemed (CHE) Lags Q3 Earnings and Revenue Estimates

Core Viewpoint - Chemed reported quarterly earnings of $5.64 per share, missing the Zacks Consensus Estimate of $5.76 per share, but showing an increase from $5.32 per share a year ago [1][2] Financial Performance - The company posted revenues of $606.18 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 1.12%, compared to $564.53 million in the same quarter last year [3] - Chemed has surpassed consensus revenue estimates just once over the last four quarters [3] Stock Performance - Chemed shares have increased approximately 4.1% since the beginning of the year, while the S&P 500 has gained 22.1% [4] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [7] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $7.05 on revenues of $641.75 million, and for the current fiscal year, it is $23.58 on revenues of $2.44 billion [8] - The trend of estimate revisions for Chemed is mixed, which could change following the recent earnings report [7] Industry Context - The Medical - Outpatient and Home Healthcare industry is currently in the top 9% of over 250 Zacks industries, indicating a favorable outlook [9] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that industry performance can significantly impact stock performance [6][9]